Fulvestrant Monotherapy After CDK4/6 Inhibitors in Metastatic Breast Cancer Patients
Author Information
Author(s): Agostini Margherita, Mandrioli Anna, Zamagni Claudio
Primary Institution: IRCCS Azienda Ospedaliero-Universitaria di Bologna
Hypothesis
What are the survival outcomes of fulvestrant monotherapy in metastatic breast cancer patients after progression on CDK4/6 inhibitors?
Conclusion
Fulvestrant monotherapy after CDK4/6 inhibitors results in poor disease control and is an inadequate therapeutic option.
Supporting Evidence
- 23 out of 30 patients progressed on fulvestrant with a median PFS of 3.7 months.
- The PFS rate was only 27% at six months and 6% at one year.
- Fulvestrant monotherapy was found to be an inadequate therapeutic option after CDK4/6 inhibitors.
Takeaway
This study looked at 30 women with breast cancer who were treated with a drug called fulvestrant after another treatment didn't work. The results showed that fulvestrant didn't help them much.
Methodology
The study evaluated 30 women with HR+/HER2- metastatic breast cancer receiving fulvestrant after progression on CDK4/6 inhibitors.
Limitations
The study is limited by its small sample size and the variability in patient responses.
Participant Demographics
Median age was 63.8 years, with a range from 43 to 89 years.
Statistical Information
Confidence Interval
95% CI, 0.63 to 0.93
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website